Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 97INDUSTRY 60NIH 32OTHER_GOV 2NETWORK 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Endocrine 1

Conditions

Thymoma 1Sarcoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Mesothelioma 1

Interventions

Capecitabine 9Bevacizumab 8tislelizumab 7Oxaliplatin 7Drug Therapy 7pembrolizumab 6Surgical Procedures, Operative 6Cisplatin 6Standard of Care 5Radiotherapy 5Laparoscopy 5Fluorouracil 5Docetaxel 5Carboplatin 5toripalimab 4Radiosurgery 4Leucovorin 4Exercise 4Epirubicin 4Cyclophosphamide 4pertuzumab 3durvalumab 3dalpiciclib 3atezolizumab 3anlotinib 3Saline Solution 3Rituximab 3Radiation 3Prednisone 3Population Groups 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × olaparib × 1 year × Clear all
NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed
603 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT04375267 2026-04-14

LuPARP

Vastra Gotaland Region

Phase 1 Completed
18 enrolled
EndocrineNETOther solid neoplasmThoracic

Mesothelioma, Thymoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡